GLP-1 Anti-Obesity U.S. Drug Market In Four Charts [zero hedge]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: zero hedge
GLP-1 Anti-Obesity U.S. Drug Market In Four Charts Beyond the most recent GLP-1 feud between Hims & Hers and Novo Nordisk, UBS analysts shift attention to anti-obesity drug trends in the U.S. market for the first week of February. Analysts led by Matthew Weston focused on new data that show new-to-brand prescriptions (NBRx) for starter doses and all doses across the major obesity GLP-1s in a series of charts: Obesity GLP-1 starter dose NBRx (up to 2/6/2026) GLP-1 starter dose NBRx trends (up to 2/6/2026) GLP-1 starter dose NBRx market share (up to 2/6/2026) Obesity GLP-1 all doses Total Prescriptions (TRx, up to 2/6/2026) Weston concluded: NBRx trends for Wegovy continue to look strong with an encouraging start to the Wegovy pill launch. The uptick in NBRx at the start of the year for Wegovy pen is also going in the right direction. Importantly, the high proportion of Wegovy NBRx pill to TRx and high proportion of Wegovy pill starter dose NBRx to total NBRx suggest that there is very
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk (CPSE:NOVO B) Valuation After A Challenging Year For Shareholders [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk: The Possible Upside [Seeking Alpha]Seeking Alpha
- Analysis-US could take action including fines against Hims after brief Wegovy copy launch [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novo Nordisk plans Wegovy vials amid obesity-drug competition [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/17/26 - Form 6-K
- 2/11/26 - Form 6-K
- 2/10/26 - Form 6-K
- NVO's page on the SEC website